Clinical Trial Update: Safety and Tolerability of Pembrolizumab (MK-3475) + Pegylated Interferon Alfa-2b and Pembrolizumab+ Ipilimumab in Participants With Advanced Melanoma or Renal Cell Carcinoma (MK-3475-029/KEYNOTE-29) [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial assessing safety and tolerability of pembrolizumab combined with pegylated interferon alfa-2b or with ipilimumab in advanced melanoma or renal c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma
• Renal Cell Carcinoma

Drugs mentioned

• Pegylated Interferon Alfa-2b (pegylated interferon alfa-2b)
• Pembrolizumab (pembrolizumab)
• ipilimumab (ipilimumab)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Renal Cell Carcinoma, Melanoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2022-05-18